Ceftazidime-Avibactam Versus Polymyxin-Based Combination Therapies: A Study on 30-Day Mortality in Carbapenem-Resistant Enterobacterales Bloodstream Infections in an OXA-48-Endemic Region

• Main Authors: Rıdvan Dumlu (Author), Meyha Şahin (Author), Okan Derin (Author), Özlem Gül (Author), Sedef Başgönül (Author), Rehile Zengin (Author), Çiğdem Arabacı (Author), Funda Şimşek (Author), Serap Gençer (Author), Ayşe Sesin Kocagöz (Author), Ali Mert (Author)
• Format: Book
• Published: MDPI AG, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<b>Background</b>: Ceftazidime-avibactam (CAZ-AVI) is recommended as first-line treatment for Oxacillinase-48 (OXA-48) β-Lactamase-producing carbapenem-resistant Enterobacterales (CRE) infections, while polymyxin-based combination therapies (PBCTs) are used as a last resort when CAZ-AVI...